ABSTRACT
Matriptase-2 (also known as TMPRSS6) is a recently identified member of the type II transmembrane serine protease (TTSP) family. Structurally this enzyme contains a short cytoplasmic amino terminal tail, a transmembrane region, a stem region containing two CUB domains and three LDL receptor class A domains, and at the carboxy terminal a trypsin-like serine protease domain. The matriptase-2 gene and encoded protein are highly conserved in mammals. Biochemically matriptase-2 has substrate specificity similar to the structurally related protein matriptase (also known as MT-SP1). Although the patho-physiological functions of matriptase-2 are not known, its high mRNA expression in liver and several cancers indicate that this enzyme, similar to other TTSPs, will likely have important cell surface associated roles in normal and disease states. Here we overview the identification of matriptase-2, summarise its structural features, biochemistry, expression pattern and disease associations and discuss its potential functions.
INTRODUCTION
Proteolytic events at the cell surface regulate many important cellular processes requiring transduction of signals across the cell surface, release of bioactive growth factors, cytokines and peptide hormones, as well as interactions with other cells and basement membrane and extracellular matrix proteins. As these processes are associated with normal physiological responses such as inflammation and proliferation, and are also co-opted to facilitate progression of diseases such as cancer, it is critical that we have a clear understanding of the proteases involved and the mechanisms regulating proteolytic activity.
Matriptase-2 (1, 2) is a member of the type II transmembrane serine protease (TTSP) family; a recently recognised family of cell surface proteolytic enzymes (3) (4) (5) (6) . Structurally, the TTSPs are characterised by a short amino terminal cytoplasmic tail, a membrane spanning domain, a stem region containing modular protein interacting For example, the heart expressed TTSP corin (7) activates pro-atrial natriuretic peptide to the active hormone critical for maintenance of blood pressure and salt-water balance (8) . In addition, expression of the gene encoding the TTSP hepsin, originally identified in liver (9) , is the most highly up-regulated gene in prostate cancer (10) (11) (12) (13) (14) . Furthermore, transgenic studies in mice indicate that hepsin has a functional role in prostate cancer progression (15) . Also, enteropeptidase, expressed on the surface of enterocytes, is the physiological activator of trypsinogen and thus essential in digestion (16) . Studies in knock-out mice indicate that matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis (17) , while expression of this TTSP in the skin of transgenic mice causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation (18) . Fusions of the ETS transcription factor genes ERG and ETV1 with the promoter of the TTSP gene TMPRSS2 is a common occurrence in prostate cancer with the overexpression of these ETS family members driven by androgen-responsive elements within the TMPRSS2 promoter (19) . TMPRSS2 expression is also upregulated in prostate cancer (20) and this enzyme activates the G protein coupled receptor, protease activated receptor 2, in prostate cancer cells (21) . Furthermore, a role for TMPRSS2 in angiogenesis is suggested by the observation that TMPRSS2 expression is up-regulated in micro-vascular endothelial cells undergoing three dimensional tubule morphogenesis (22) . The nonmammalian TTSP stubble-stubbloid is required for hormone-dependent epithelial morphogenesis of imaginal discs of Drosophila, including the formation of bristles, legs, and wings (23) . Finally, insertion of beta-satellite repeats into the TMPRSS3 gene causes both congenital and childhood onset autosomal recessive deafness (24) .
Although the functions of other TTSP family members have not been determined, the restricted expression patterns and method of identification of several of these enzymes are suggestive of significant roles. For example, TMPRSS4 (formerly designated TMPRSS3) is overexpressed in pancreatic cancer (25) , while the epithelial cell specific TTSP, DESC-1 (26, 27) , is downregulated during squamous cell carcinoma progression and upregulated during normal epithelial differentiation (28) . TMPRSS5, which is expressed in neuronal axons and at the synapses of motoneurons in the spinal cord, is thought to function at the surface of synapses to activate or inactivate other proteins (29) . The human airway trypsin-like (HAT) TTSP, originally isolated from the sputum of patients with chronic airway diseases (30) , has been proposed to have a role in these diseases because of its ability to mediate inflammatory responses such as increased mucus production (31) and TNFα activity (32) . Other members of the TTSP family for which patho-physiological roles have not been determined include the mammalian enzymes matriptase-3 (33), polyserase-I (34), MSPL (5, 35) , and the DESC/HAT-like proteases (5, 26, 36, 37) as well as the Xenopus laevis protease Xesp-2 (38).
IDENTIFICATION
The matriptase-2 cDNA was identified in human (1) and mouse (2) using in silico approaches. The complete human cDNA was cloned from fetal liver and named on the basis of its significant structural similarity to the TTSP matriptase/MT-SP1 (1). The mouse coding sequence was identified from an expressed sequence tag clone generated from adult liver (2) . The mouse and rat encoded proteins were originally designated Tmprss6 on the basis of TTSP nomenclature (2), however, for consistency the matriptase-2 designation is now applied across all species. The complete sequence of matriptase-2 in macaque, dog and cow and a partial sequence in chimpanzee have also recently been deposited into sequence databases (Table 1 ).
STRUCTURAL FEATURES AND BIOCHEMISTRY
As shown in Figure 1 matriptase-2 has all the structural features of a TTSP including a short cytoplasmic amino terminal tail, a transmembrane region, a stem region containing two complement protein subcomponents C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1 (CUB) domains and three low density lipoprotein receptor class A (LDLR) domains, and at the carboxy terminal a trypsin-like serine protease domain. These structural features are absolutely conserved across human, macaque, dog, cow, mouse and rat ( Figure  2 ), with the human protein sharing 95.6% (775/811), 91.1% (739/811), 85.6% (694/811), 80.1% (650/811) and 80.4% (652/811) identity, respectively, to matriptase-2 from these species. Consistently, by Western blot analysis of lysates from transiently transfected cells, both human (1) and mouse (2) matriptase-2 migrate close to the predicted molecular mass of ~90kDa.
In addition to conserved structural domains, matriptase-2 contains conserved consensus N-glycosylation sites and cysteine residues. Three consensus Nglycosylation sites are present within the region between the transmembrane domain and the first CUB domain. Three other sites occur within the second CUB domain and one within LDLR2. The lack of consensus N-glycosylation sites in the serine protease domain is in contrast to the majority of other TTSPs. However, HAT (30) , Hepsin (9), TMPRSS2 (20) and TMPRSS4 (25) also lack glycosylation in this region. Matriptase-2 also has a high content of cysteines -37 extracellular cysteines are conserved in all species. On the basis of the crystal structure of the spermadhesin porcine seminal plasma (PSP)-I-PSP-II heterodimer (39), cysteines C2/C3 and C4/C5 (numbering per Figure 2 ) form disulfide bonds in CUB1 and cysteines C6/C7 and C8/C9 within CUB2. Similarly, on the basis of the structure of the LDLR extracellular domain (40) , cysteines C10/C12, C11/C14 and C13/C15 form disulfide bonds within LDLR1, C16/C18, C17/C20 and C19/C21 within LDLR2 and C22/C24, C23/C26 and C25/C27 within LDLR3. The following disulfide bonds form within the serine protease domain C29/C30, C32/C36, C33/C34 and C35/C37 and the pro and catalytic regions are linked by the C28/C31 pair. Finally, cysteine C1 of matriptase-2 is unpaired intramolecularly and therefore has the potential to form homo-or hetero-linkages (2).
As well as conserved disulfide bond forming cysteines, the matriptase-2 proteolytic domain has all the features common to members of the serine protease S1 family. These include the serine protease triad of 617 H, 668 D, and 762 Ser residues (human numbering) required for catalytic activity, and an SWG motif predicted to be located at the top of the substrate S1 binding pocket positioning the scissile bond of the substrate in the correct orientation. Proteolytic activation of matriptase-2 is predicted to occur within a motif ( 576 RIVGG) at the junction of the pro-and catalytic domains which is characteristic of serine proteases and conserved across species. Consistent with the presence of an aspartate residue, 6 amino acids before the catalytic serine, which specifies preference for trypsin-like serine protease cleavage following arginine or lysine residues, the recombinant matriptase-2 protease domain cleaves following arginine but not alanine. Interestingly and in contrast to the substrate specificity of the structurally similar TTSP matriptase/MT-SP1 (1, 41), the active recombinant matriptase-2 protease domain does not cleave following lysine (1) . The authors explained this difference in peptide substrate specificity using a model of matriptase-2 based on the crystal structure of matriptase/MT-SP1 (42) . Their analysis showed that matriptase/MT-SP1 residue 190 S permits access of both arginine and lysine residues in the S1 pocket whereas an alanine at this position in matriptase-2 permits accommodation of arginine (1) . Consistent with the serine protease classification of matriptase-2, its activity against tripeptide substrates was completely abolished by inhibitors of trypsin-like serine proteases (PMSF, AEBSF, leupeptin and aprotinin) but not by an inhibitor of chymotrypsin-like serine proteases (TPCK) or inhibitors of metallo (EDTA) or cysteine (E-64) proteases (1).
Figure 2.
Multiple sequence alignment. Matriptase-2 protein sequences were aligned using the EclustalW algorithm (Australian National Genome Information Service website). The transmembrane domain was identified using the TMHMM algorithm and matriptase-2 sequences were analysed for modular protein domains using the SMART algorithm (ExPASy Proteomics Tools website). Underlined domains: CUB, complement protein subcomponents C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1 domain; LDLR, low density lipoprotein receptor class A domain. A region with lower homology to sea urchin sperm protein, enteropeptidase, agrin (SEA) domains is underlined by a dashed line. Consensus N-glycosylation sites are indicated N1 to N7. Cysteines are numbered C1 to C37. The catalytic histidine, aspartate and serine residues necessary for serine protease activity are indicated by "H", "D" and "S" respectively. The activation site is indicated by an arrow. Sequences were obtained from the following GenBank entries: Human NP_705837; Macaque XP_001085319; Dog XP_531743; Cow XP_871580; Mouse NP_082178; Rat XP_235768.
Against macromolecular extracellular matrix (ECM) and basement membrane components, the recombinant matriptase-2 catalytic domain was able to cleave the ECM proteins fibronectin, fibrinogen and type I collagen in vitro but not the basement membrane protein laminin (1) . In addition, the authors noted that matriptase-2 is not a bona fide collagenase as it did not generate the ¾ and ¼ fragments typical of fibrillar collagenases. The matriptase-2 serine protease domain was also incapable of activating the pro forms of the matrix metalloproteases MMP-2 or MMP-9 or the serine protease plasminogen, but was a low efficiency activator of pro-uPA (1). Interestingly, this domain which was generated in bacteria, was subject to autoactivation at 37°C, releasing the proteolytic region from its GST fusion (1). In contrast, in a mammalian cell system transiently over expressing mouse matriptase-2, there was no evidence by Western blot analysis under reducing conditions that the protease had been activated (2) . This suggests that autoactivation of endogenous matriptase-2 may not be possible, potentially because the presence of the endogenous activation domain and stem region provide an inhibitory mechanism against auto-catalytic activity. Therefore, proteolytic activation of the matriptase-2 zymogen may represent a post-translation mechanism of controlling the catalytic activity of this TTSP.
In addition to these structural domains, matriptase-2 also contains a region spanning residues 83 to 186 (human numbering) which has low identity to sea urchin sperm protein, enteropeptidase, agrin (SEA) domains. In other SEA domain containing, membrane spanning proteins, autoproteolysis, following a glycine residue within a conserved motif (eg. GSVVV (43)), releases these molecules from the cell surface. Proteolysis within this conserved motif, which is located near the middle of the SEA domain, is catalysed by conformational stress and the hydroxyl of the serine present within the motif (43) . Release from the cell surface by cleavage within a similar SEA domain motif has been reported for the TTSPs porcine enteropeptidase (44) and mouse matriptase/MT-SP1 (45) at the respective cleavage sites 117 GSVIV and 149 GSVIA. Another member of the TTSP family, HAT, contains a similarly located site ( 109 GSGVR) within its SEA domain. In contrast the SEA domain-like region of matriptase-2 and the SEA domain of other TTSPs, such as mouse matriptase-3 (33) and DESC1 (26) , lack a consensus cleavage site near the middle of the domain. However, the matriptase-2 SEA domain-like region contains a cleavage motif-like sequence ( 90 GSLRV) proximal to its amino terminal whereas the mouse matriptase-3 SEA domain has the sequence 201 GSLQG near to its carboxy terminal. Whether cleavage within these motifs mediates release of these TTSPs from the cell surface has not been examined.
The role of each of these structural features in regulating matriptase-2 function has not yet been addressed. Clearly the cell surface location and orientation of matriptase-2, which have been confirmed for both the human (1) and mouse (2) proteins by confocal microscopy analysis of transiently transfected cells, provide a level of spatial regulation of the protease domain. It is also possible that the matriptase-2 cytoplasmic tail will modulate protein function. However, none of the matriptase-2 consensus phosphorylation sites are conserved across species, suggesting that phosphorylation of this protein is either not essential to its function or is unique to each organism. Furthermore, additional regulation of matriptase-2 activity will likely be achieved via its two CUB and three LDLR domains, and possibly also involve the region spanning the low-identity SEA domain. Each of these domains is common amongst TTSP family members (3-6) and, in particular, many CUB domain containing proteins are proteases (46) . Accordingly, it will be of interest to determine whether the matriptase-2 CUB domains are involved in oligomerization or recognition of substrates as is the case for other proteins (46) , and similarly, whether the LDLR domains of this TTSP mediate interactions with macromolecules such as serine protease:inhibitor complexes and lipoproteins (47). Figure 3 , the matriptase-2 gene is highly conserved across mammalian species and ranges in size from ~29 kb in mouse to ~40 kb in chimpanzee. Each gene spans 18 exons with 17 intervening introns, with the size and junctions of 14 of the exons absolutely conserved. Also, although the size of the last exon varies, the size of the coding sequence of this exon is conserved at 159 nucleotides. Each of the mammalian matriptase-2 genes is located in a genomic region devoid of other TTSP genes. This is similar to other TTSP genes such as corin (7) and hepsin (48) and in contrast to TMPRSS4 (25) and TMPRSS5 (29) which both localise to human chromosome region 11q23.3, TMPRSS2 (49) and TMPRSS3 (24) to 21q22 and the HAT, HAT-like, DESC and DESC-like encoding genes which localise to 4q11 (5) . Sequences at the 5' and 3' end of each intron conform to the GT-AG rule for splice-site recognition (50) except for the 5' end of the first human, chimpanzee and macaque intron which has GC instead of GT. All matriptase-2 protein domain boundaries correspond with intron/exon junctions of the encoding gene across all species ( Figure 3A) . The first CUB domain is encoded by two exons (7 and 8) , and the second CUB domain by three exons (9 to11). The three LDLR domains of matriptase-2 are each encoded by separate exons (12, 13 and 14) . Finally, the serine-protease domain, including the activation domain, is encoded by four exons (15 to 18).
GENE STRUCTURE AND REGULATION

As indicated in
Variation occurs between lower and higher mammals towards the 5' end of the matriptase-2 gene. In human, chimpanzee and macaque the initiating codon is located in exon 1 whereas in rodents this codon is in exon 2. The size of the intron interrupting the first two exons in these species is also different. In human, chimpanzee and macaque the first exon is only 95 nucleotides upstream of exon 2 whereas in rodents these exons are separated by an intron greater than 4.5 kb in size. At the protein level this variation appears to have little effect. As shown in Figure 2 , the rodent protein extends 3 residues beyond the amino terminal of the human and macaque protein (the complete chimpanzee protein is currently not available). In addition, both human and mouse matriptase-2 localise efficiently to the cell surface in cells transiently transfected with the corresponding expression constructs (1, 2) . Other contrasting features across matriptase-2 genes are the size of exons 2 and 5. In human and chimpanzee, exon 2 is 203 nucleotides whereas in macaque, cow and dog it is 197 nucleotides and 235 nucleotides in rodents. The availability of sequence for exon 1 and intron A of cow and dog, will likely indicate the evolution of this, the major region of variation across these mammalian species. In addition, whereas exon 5 is 185 nucleotides in human, chimpanzee, macaque, cow and dog, this exon is 179 nucleotides in rodents. This variation leads to the rodent protein being 2 residues shorter in the SEA domain-like region immediately before the second matriptase-2 consensus Nglycosylation site.
There is also evidence that mammalian matriptase-2 genes are capable of generating multiple mRNA splice variants. For example in human, several splice variants are predicted to encode matriptase-2 isoforms; one truncated after the middle of the second CUB domain (GenBank accession number EAW60141) and another with amino acid insertions before both the first CUB domain and the protease activation domain (GenBank accession number CAK54774). This last isoform is also predicted from a dog mRNA splice variant (GenBank accession number XP_850550). Another dog splice variant, generated by skipping exon 6, is predicted to translate a protein lacking 14 matriptase-2 residues immediately before the first CUB domain (GenBank accession number XP_531743). The rat gene generates mRNA splice variants encoding the full-length protein shown in Figure 2 as well as an isoform lacking the transmembrane domain predicted to be a secreted protein (2) . It is clear that several of the generated protein isoforms will be functionally different to the full-length protein. In particular, these include isoforms predicted to be secreted proteins and those lacking the serine protease catalytic domain. Therefore, it will be important to determine the mechanisms regulating the generation of matriptase-2 mRNA splice variants as well as the mechanisms controlling transcription of the matriptase-2 gene generally. Currently, there has been only one report of matriptase-2 gene regulation and this demonstrated gonadotropin mediated down-regulation of transcription in mouse testis Leydig cells (51).
EXPRESSION PATTERN AND DISEASE ASSOCIATION
The expression of matriptase-2 mRNA in adult and embryonic tissues, during embryonic development and in cancers is shown in Table 2 . In human, mouse and rat, liver is the common site of abundant matriptase-2 mRNA expression (1, 2) . This pattern of expression in one or a few tissues, is consistent with the restricted transcription of other TTSP genes and also with the proposal that the encoded proteins have tissue-specific functions (4). For example, enteropeptidase expression is restricted to enterocytes of the proximal small intestine where it activates trypsinogen (52), while corin is predominantly produced by heart myocytes where it activates pro-ANP (7).
Each of these proteolytic activation events occurs on the surface of these cells. Other TTSPs also have restricted expression patterns including TMPRSS2 in prostate and colon (49, 54) , hepsin in liver and kidney (48, 55) , and DESC1 in epithelial locations (27) . Accordingly, it will be important to determine the role of matriptase-2 on the surface of cells in the liver.
Our analysis of the GenBank Unigene database indicated that human matriptase-2 mRNA is also expressed strongly in adrenal gland and brain with lower levels in lung, testis and uterus. Interestingly, the sites of highest expression in normal human tissues (liver, adrenal gland, brain and uterus) are also sites of high expression in cancer ( Table 2 ). In addition, Velasco et al. have noted that the region containing the matriptase-2 gene is frequently altered in other human cancers, including insulinomas, ependymomas, and colorectal and breast carcinomas (1) . Significantly, two other recent reports also indicate an association of matriptase-2 with breast cancer. A proteomics approach indicated elevated levels of matriptase-2 protein in invasive ductal breast carcinoma (56) , while an epidemiological approach suggested that the matriptase-2 gene is associated with breast cancer risk in an Eastern Finnish population (57) . To determine whether matriptase-2 is differentially expressed in these cancers, studies are needed comparing its expression in a defined population of matched non-diseased and cancerous samples.
RT-PCR and in situ hybridization analyses provided significant insight into the cells expressing matriptase-2 mRNA in adult and embryonic mouse tissues (2) . In adult tissues, in addition to liver, kidney was also a site of high matriptase-2 mRNA expression with lower levels in uterus and much smaller amounts detected in many other tissues. In liver matriptase-2 mRNA was expressed by hepatocytes, whereas expression was consistent throughout kidney with glandular columnar epithelial cells the predominant site in uterus. In embryos matriptase-2 mRNA expression peaked at day 13.5 post coitus. In addition to high expression in liver, matriptase-2 mRNA was strongly detected in olfactory epithelial cells of the nasal cavity and in pharyngo-tympanic tubes. These data suggest roles for matriptase-2 in adult tissues as well as during embryogenesis. In addition, the overlapping expression of matriptase-2 and hepsin mRNA in embryonic and adult mouse suggested some extent of functional redundancy of these proteins.
CONCLUSION
Although the function of matriptase-2 is not known, a number of observations point to key roles for this protein in a restricted set of tissues and, potentially, in a number of cancers. These data also indicate that matriptase-2 will function by cleaving a limited repertoire of substrates/inhibitors and by interacting with other proteins via its non-catalytic domains. For example, the ability of matriptase-2 to cleave fibrinogen suggests that this enzyme will be involved in processes requiring fibrin formation such as angiogenesis (1) which is necessary for progression of several diseases including cancer. In addition, the abundant expression of matriptase-2 mRNA in the liver of human and rodents suggests that the encoded protein will function in this tissue and, if released from the cell surface, will also have a role as a circulating enzyme as is the case for other trypsin-like serine proteases involved in processes such as blood coagulation (58) and tissue remodelling in cancer (59, 60) . In fact it is possible that the cell surface location and proteolytic activity of matriptase-2 will facilitate cancer progression as is the case for other TTSPs including hepsin (15) and matriptase/MT-SP1 (18).
It is clear that the functions of matriptase-2 in normal physiology and disease will be regulated at a number of levels. At the transcriptional level the matriptase-2 gene is capable of generating multiple splice variants, several of which, at least, will translate protein isoforms with differing functions. Also, the restricted expression pattern of matriptase-2 mRNA suggests that transcription is tightly regulated. Furthermore, it is likely that the unpaired cysteine of matriptase-2, which is located between the transmembrane domain and the first CUB domain, will be involved in homo-or hetero-meric linkages which will regulate protein function. In addition, the location of matriptase-2 at the cell surface will provide a level of regulation by restricting access of the protease to potential substrates and also by requiring a mechanism, such as proteolysis, to release the protein from the cell surface. Release from the cell surface may also be mediated via transcriptional events which generate mRNA splice variants encoding a secreted form of the protein.
As has been the case for other members of the TTSP family including corin (8) , hepsin (15) and matriptase/MT-SP1 (17, 18, 61) , it is likely that greatest progress on the patho-physiological roles of matriptase-2 will occur using either knock-out or transgenic mice. It has also been suggested that the overlapping expression of matriptase-2 and hepsin in mice indicates a level of functional redundancy which will require the careful analysis of matriptase-2 knock-out mice and, potentially, the generation of matriptase-2/hepsin double knock-out mice (2) .
